Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors
<b>Background</b>: Anterior uveitis (AU) is a significant concern in patients with ankylosing spondylitis (AS), and the choice of tumor necrosis factor inhibitors (TNFi) as a treatment modality raises questions regarding its effects on AU. We compared the effects of TNFi on AU in patient...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/3/912 |
| _version_ | 1797318531299147776 |
|---|---|
| author | Hyeon Yoon Kwon Yu Jeong Kim Tae-Hwan Kim Seong Joon Ahn |
| author_facet | Hyeon Yoon Kwon Yu Jeong Kim Tae-Hwan Kim Seong Joon Ahn |
| author_sort | Hyeon Yoon Kwon |
| collection | DOAJ |
| description | <b>Background</b>: Anterior uveitis (AU) is a significant concern in patients with ankylosing spondylitis (AS), and the choice of tumor necrosis factor inhibitors (TNFi) as a treatment modality raises questions regarding its effects on AU. We compared the effects of TNFi on AU in patients with AS. <b>Methods</b>: Patients diagnosed with AS and treated with at least one TNFi, including anti-TNFα antibodies (adalimumab and infliximab) or a soluble TNF receptor molecule (etanercept), between January 2010 and December 2022, were retrospectively reviewed. We compared the recurrence rate of AU in patients with a history of uveitis and the incidence of new-onset AU in those without a history of uveitis among the three TNFi groups. We also compared the effects of two different TNFi agents in patients who underwent TNFi switching. <b>Results</b>: Within two years of treatment initiation, there was no significant difference in AU recurrence among the three TNFi groups. However, the incidence of new-onset AU was significantly higher in the etanercept group than in the adalimumab group (26.4% vs. 6.3%; <i>p</i> = 0.024). After two years, the AU recurrence rate was significantly lower in the adalimumab group than in the other groups (<i>p</i> < 0.001). Among patients who underwent anti-TNFi switching, adalimumab treatment was associated with a significantly lower incidence of uveitis than etanercept (<i>p</i> = 0.023). <b>Conclusion</b>: In the short-term period following TNFi therapy, etanercept induced new-onset AU more frequently than adalimumab in patients with AS. Adalimumab recipients experienced fewer AU recurrences during the subsequent long-term period compared to other TNFi recipients. |
| first_indexed | 2024-03-08T03:53:47Z |
| format | Article |
| id | doaj.art-7f8a20eec8f94fcbbc580b1ddcfadd0b |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T03:53:47Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-7f8a20eec8f94fcbbc580b1ddcfadd0b2024-02-09T15:16:51ZengMDPI AGJournal of Clinical Medicine2077-03832024-02-0113391210.3390/jcm13030912Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor InhibitorsHyeon Yoon Kwon0Yu Jeong Kim1Tae-Hwan Kim2Seong Joon Ahn3Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of KoreaDepartment of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of KoreaDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University College of Medicine, Seoul 04763, Republic of KoreaDepartment of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea<b>Background</b>: Anterior uveitis (AU) is a significant concern in patients with ankylosing spondylitis (AS), and the choice of tumor necrosis factor inhibitors (TNFi) as a treatment modality raises questions regarding its effects on AU. We compared the effects of TNFi on AU in patients with AS. <b>Methods</b>: Patients diagnosed with AS and treated with at least one TNFi, including anti-TNFα antibodies (adalimumab and infliximab) or a soluble TNF receptor molecule (etanercept), between January 2010 and December 2022, were retrospectively reviewed. We compared the recurrence rate of AU in patients with a history of uveitis and the incidence of new-onset AU in those without a history of uveitis among the three TNFi groups. We also compared the effects of two different TNFi agents in patients who underwent TNFi switching. <b>Results</b>: Within two years of treatment initiation, there was no significant difference in AU recurrence among the three TNFi groups. However, the incidence of new-onset AU was significantly higher in the etanercept group than in the adalimumab group (26.4% vs. 6.3%; <i>p</i> = 0.024). After two years, the AU recurrence rate was significantly lower in the adalimumab group than in the other groups (<i>p</i> < 0.001). Among patients who underwent anti-TNFi switching, adalimumab treatment was associated with a significantly lower incidence of uveitis than etanercept (<i>p</i> = 0.023). <b>Conclusion</b>: In the short-term period following TNFi therapy, etanercept induced new-onset AU more frequently than adalimumab in patients with AS. Adalimumab recipients experienced fewer AU recurrences during the subsequent long-term period compared to other TNFi recipients.https://www.mdpi.com/2077-0383/13/3/912anterior uveitisankylosing spondylitistumor necrosis factor inhibitors |
| spellingShingle | Hyeon Yoon Kwon Yu Jeong Kim Tae-Hwan Kim Seong Joon Ahn Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors Journal of Clinical Medicine anterior uveitis ankylosing spondylitis tumor necrosis factor inhibitors |
| title | Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors |
| title_full | Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors |
| title_fullStr | Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors |
| title_full_unstemmed | Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors |
| title_short | Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors |
| title_sort | comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors |
| topic | anterior uveitis ankylosing spondylitis tumor necrosis factor inhibitors |
| url | https://www.mdpi.com/2077-0383/13/3/912 |
| work_keys_str_mv | AT hyeonyoonkwon comparisonofincidenceorrecurrenceofanterioruveitisinpatientswithankylosingspondylitistreatedwithtumornecrosisfactorinhibitors AT yujeongkim comparisonofincidenceorrecurrenceofanterioruveitisinpatientswithankylosingspondylitistreatedwithtumornecrosisfactorinhibitors AT taehwankim comparisonofincidenceorrecurrenceofanterioruveitisinpatientswithankylosingspondylitistreatedwithtumornecrosisfactorinhibitors AT seongjoonahn comparisonofincidenceorrecurrenceofanterioruveitisinpatientswithankylosingspondylitistreatedwithtumornecrosisfactorinhibitors |